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We thank Dr. Cheung et al. for their thoughtful comments on our
recent article published in the Journal of Hepatology. Several
important issues are raised. The ﬁrst one is about the time of
maternal blood sampling. In our study, the testing of maternal
hepatitis B e antigen (HBeAg) and viral load after delivery might
be suboptimal, but the concordance of HBeAg results with those
tested at prenatal screening provided evidence that the HBeAg
results, although some were tested postpartum, could represent
the HBeAg status at delivery. All the 81 HBeAg-positive mothers
and 98.6% (219/222) HBeAg-negative mothers in our study had
concordant HBeAg results with prenatal screening. The 3 mothers
with HBeAg seroconversion had HBeAg and HBV DNA tested
before or on the day of delivery. The median time of maternal
blood sampling was 2 days post-partum.
Post-partum viral load decline was found in some hepatitis B
surface antigen (HBsAg)-positive mothers because a minority of
HBeAg-positive mothers may become HBeAg-negative after
delivery [1]. For those mothers remaining HBeAg-positive post-
partum, the viral loads tested till 1 year postpartum were similar
to those tested prior to or at delivery [1,2]. In a recent study of
telbivudine to reduce maternal HBV transmission, 35 HBeAg-
positive mothers with a viral load above 106 copies/ml in the con-
trol group had comparable high viral loads from pregnancy until
28 weeks postpartum [3]. The above studies support our data
that HBsAg-positive mothers have stable viral loads from delivery
to several months postpartum if their HBeAg status does not
change after delivery. We therefore believe that our maternal
viral load data are representative of the peripartum viral load
status.
Dr. Cheung also mentioned that the result would be more
meaningful if the viral load levels were obtained before 28 weeks
of gestation because antiviral therapy was started from 28 weeks
of gestation in most of the trials to decrease mother-to-infant
transmission. We agree that antiviral therapy needs time to
achieve signiﬁcant viral suppression before delivery. However,
the majority of mother-to-infant transmission is thought to occur
during labor and delivery [4,5]. We think that the viral load tested
at the peripartum stage represents the viral load level at which
most mother-to-infant transmissions occur.
Secondly, none of our HBsAg-positive mothers received anti-
viral therapy during the study period. Thirdly, we agree that hor-
izontal transmission was possible in 17.5% of children tested for
HBsAg at 1–3 years of age. HBsAg-positive mothers transmit
HBV to their children not only in the perinatal stage but also in
the post-natal stage [6]. HBV infection acquired at 1–3 years of
age could result from maternal transmission. Finally, amniocen-
tesis has not been shown to signiﬁcantly increase rates of HBV
transmission [7]. In Taiwan, the recommended schedule for theJournal of Hepatology 201ﬁrst dose of HBV vaccine was 3–5 days after birth before 2012;
and the schedule has been updated to within 24 hours of birth
since 2012. The 10 HBV-infected infants and those infants
without chronic HBV infection had comparable rates of amnio-
centesis or chorionic villus sampling (50% vs. 46.4%, p = 0.821)
and received the 1st HBV vaccine dose at similar ages (5.6 ± 5.3
vs. 3.8 ± 3.2 day, p = 0.0958) in our study.3 vol. 59 j 396–402 401
